The FDA has delayed approval of an application for the first human embryonic stem cell clinical trial by Geron Corporation, the company linkurl:announced;http://www.geron.com/media/pressview.aspx?id=840 yesterday. Geron's compound, GRNOPC1, is a cell-based therapy to treat spinal cord injury. Yesterday, the FDA told Geron verbally that they were placing the Investigational New Drug submission of the treatment under a clinical hold. The company is awaiting a formal letter. Thomas Okarma, Geron's president and chief executive officer, said in a press release: "We are disappointed with this action given the interactions we had with the FDA over four years leading to the filing, and the breadth and depth of the submission, some 21,000 pages, predicated on those discussions with the agency." Ren Benjamin, an analyst with Rodman & Renshaw, told linkurl:Bloomberg News;http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aEz5ggrE0.HU that the FDA's decision was not surprising. The agency held a linkurl:meeting last month;http://www.the-scientist.com/blog/display/54544/ to consider what guidelines to recommend for sponsors...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!